Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).

被引：0
|
作者：
Skelton, William Paul [1 ]
Jain, Rohit K. [2 ]
Curran, Catherine [3 ]
Pond, Gregory Russell [4 ]
Naqvi, Syeda Mahrukh Hussnain [5 ]
Kim, Youngchul [1 ]
Nuzzo, Pier Vitale [3 ]
Abou Alaiwi, Sarah [3 ]
Nassar, Amin [6 ]
Jain, Rakesh K. [7 ]
Sonpavde, Guru [8 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
453
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-kyo
    Lee, Jae Lyun
    CLINICAL GENITOURINARY CANCER, 2020, 18 (02) : E122 - E133
  • [32] PD1 Blockade in Cancer: Impact on Myeloid Cells
    Fujiwara, Mai
    Garo, Lucien P.
    Murugaiyan, Gopal
    TRENDS IN CANCER, 2020, 6 (06): : 443 - 444
  • [33] Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts)
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [34] PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma
    Brown, Landon C.
    Zhu, Jason
    Labriola, Matthew K.
    Wu, Yuan
    Cheris, Sachica
    Liu, Xin
    Perkinson, Kathryn
    Su, Zuowei
    McCall, Shannon
    Huang, Jiaoti
    Foo, Wen-Chi
    Gupta, Rajan T.
    Armstrong, Andrew J.
    George, Daniel J.
    Harrison, Michael R.
    Zhang, Tian
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 509 - 513
  • [35] Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).
    Agarwal, Archana
    Nassar, Amin
    Pond, Gregory Russell
    Barletta, Justine A.
    Acosta, Andres
    Abou Alaiwi, Sarah
    Curran, Catherine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [36] C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma
    Kluemper, Niklas
    Sikic, Danijel
    Saal, Jonas
    Buettner, Thomas
    Goldschmidt, Franziska
    Jarczyk, Jonas
    Becker, Philippe
    Zeuschner, Philip
    Weinke, Maximilian
    Kalogirou, Charis
    Breyer, Johannes
    Burger, Maximilian
    Nuhn, Philipp
    Tully, Karl
    Roghmann, Florian
    Bolenz, Christian
    Zengerling, Friedemann
    Wirtz, Ralph M.
    Muders, Michael
    Kristiansen, Glen
    Bald, Tobias
    Ellinger, Joerg
    Wullich, Bernd
    Hoelzel, Michael
    Hartmann, Arndt
    Erben, Philipp
    Ritter, Manuel
    Eckstein, Markus
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 13 - 22
  • [37] A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
    Nassar, Amin H.
    Mouw, Kent W.
    Jegede, Opeyemi
    Shinagare, Atul B.
    Kim, Jaegil
    Liu, Chia-Jen
    Pomerantz, Mark
    Harshman, Lauren C.
    Van Allen, Eliezer M.
    Wei, Xiao X.
    McGregor, Bradley
    Choudhury, Atish D.
    Preston, Mark A.
    Dong, Fei
    Signoretti, Sabina
    Lindeman, Neal I.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Sonpavde, Guru
    Kwiatkowski, David J.
    BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 555 - 563
  • [38] A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
    Amin H. Nassar
    Kent W. Mouw
    Opeyemi Jegede
    Atul B. Shinagare
    Jaegil Kim
    Chia-Jen Liu
    Mark Pomerantz
    Lauren C. Harshman
    Eliezer M. Van Allen
    Xiao X. Wei
    Bradley McGregor
    Atish D. Choudhury
    Mark A. Preston
    Fei Dong
    Sabina Signoretti
    Neal I. Lindeman
    Joaquim Bellmunt
    Toni K. Choueiri
    Guru Sonpavde
    David J. Kwiatkowski
    British Journal of Cancer, 2020, 122 : 555 - 563
  • [39] Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
    Simona Serratì
    Michele Guida
    Roberta Di Fonte
    Simona De Summa
    Sabino Strippoli
    Rosa Maria Iacobazzi
    Alessandra Quarta
    Ivana De Risi
    Gabriella Guida
    Angelo Paradiso
    Letizia Porcelli
    Amalia Azzariti
    Molecular Cancer, 21
  • [40] PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
    Stenehjem, David D.
    Tran, Dao
    Nkrumah, Michael A.
    Gupta, Shilpa
    ONCOTARGETS AND THERAPY, 2018, 11 : 5973 - 5989
12345